Michael D. Roth

12.9k citations

125 papers · 6.9k indexed · h-index 51

Impact in

Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune Response and Inflammation
Pathology and Forensic Medicine top 0.5%
- Systemic Sclerosis and Related Diseases

Papers in

Pathology and Forensic Medicine 47
- Systemic Sclerosis and Related Diseases 42
Immunology 41
- Immunotherapy and Immune Responses 22
- Immune Cell Function and Interaction 20
- T-cell and B-cell Immunology 8
- Immune Response and Inflammation 8

Co-authors: Donald P. Tashkin Sylvia M. Kiertscher Steven M. Dubinett Gayle Cocita Baldwin Jonathan Goldin Philip J. Clements Dinesh Khanna Robert M. Elashoff
Journals: CHEST Journal (9 papers)Annals of the Rheumatic Diseases (7 papers)American Journal of Respiratory and Critical Care Medicine (6 papers)Journal of Leukocyte Biology (5 papers)Journal of Neuroimmune Pharmacology (5 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Michael D. Roth

120 papers receiving 6.7k citations

Peers

Countries citing papers authored by Michael D. Roth

Since Specialization

Citations

This map shows the geographic impact of Michael D. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Roth more than expected).

Fields of papers citing papers by Michael D. Roth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Roth. The network helps show where Michael D. Roth may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael D. Roth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael D. Roth Line = papers co-authored together Michael D. Roth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis Seminars in Arthritis and Rheumatism ·Elizabeth R. Volkmann, Donald P. Tashkin, Michael D. Roth, Ning Li, Julio Charles, Maureen D. Mayes, Grace Kim, Jonathan Goldin, Lila Pourzand, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Robert M. Elashoff, Shervin Assassi	2020	4
2	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II) American Journal of Respiratory and Critical Care Medicine ·Suzanne Kafaja, Philip J. Clements, Holly Wilhalme, Chi‐Hong Tseng, Daniel E. Furst, Grace Hyun J. Kim, Jonathan Goldin, Elizabeth R. Volkmann, Michael D. Roth, Donald P. Tashkin, Dinesh Khanna	2017	86
3	Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II CHEST Journal ·Donald P. Tashkin, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Jonathan Goldin, Eric C. Kleerup, Edgar Arriola, Chi‐Hong Tseng, Robert Elashoff	2015	4
4	Lung Cancer Chemoprevention with Celecoxib in Former Smokers Cancer Prevention Research ·Jenny T. Mao, Michael D. Roth, Michael C. Fishbein, Denise R. Aberle, Zuo‐Feng Zhang, Jian Rao, Donald P. Tashkin, Lee Goodglick, E. Carmack Holmes, Robert B. Cameron, Steven M. Dubinett, Robert M. Elashoff, Éva Szabó, David Elashoff	2011	65
5	Adverse Events during the Scleroderma Lung Study The American Journal of Medicine ·Daniel E. Furst, Chi‐Hong Tseng, Philip J. Clements, Charlie Strange, Donald P. Tashkin, Michael D. Roth, Dinesh Khanna, Ning Li, Robert M. Elashoff, Dean E. Schraufnagel	2011	24
6	High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease CHEST Journal ·Jonathan Goldin, David A. Lynch, Diane C. Strollo, Robert D. Suh, Dean E. Schraufnagel, Philip J. Clements, Robert M. Elashoff, Daniel E. Furst, Sarinnapha M. Vasunilashorn, Michael F. McNitt‐Gray, Mathew S. Brown, Michael D. Roth, Donald P. Tashkin	2008	176
7	Recreational Drug Use and Risk of Kaposi's Sarcoma in HIV- and HHV-8-Coinfected Homosexual Men AIDS Research and Human Retroviruses ·Chun C. Chao, Lisa P. Jacobson, Frank J. Jenkins, Donald P. Tashkin, Otoniel Martı́nez-Maza, Michael D. Roth, Leslie J. Ng, Joseph B. Margolick, Joan S. Chmiel, Zuo‐Feng Zhang, Roger Detels	2008	9
8	Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse Life Sciences ·Michael D. Roth, Donald P. Tashkin, Katherine Whittaker, Ruth Choi, Gayle Cocita Baldwin	2005	50
9	Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL Gene Therapy ·Airi Harui, Michael D. Roth, Sylvia M. Kiertscher, K Mitani, Sayan Basak	2004	20
10	Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. PubMed ·Jenny T. Mao, Michael D. Roth, Kenneth J. Serio, Felicita Baratelli, Li Zhu, E. Carmack Holmes, Robert M. Strieter, Steven M. Dubinett	2003	38
11	All- trans Retinoic Acid Modulates the Balance of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Patients With Emphysema * CHEST Journal ·Jenny T. Mao, Donald P. Tashkin, Paula Belloni, Irene Bailey, Felicita Baratelli, Michael D. Roth	2003	56
12	Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells Journal of Neuroimmunology ·Michael Yuan, Sylvia M. Kiertscher, Qingwen Cheng, Richard A. Zoumalan, Donald P. Tashkin, Michael D. Roth	2002	183
13	Helper-Dependent Adenoviral Vectors Efficiently Express Transgenes in Human Dendritic Cells but Still Stimulate Antiviral Immune Responses The Journal of Immunology ·Michael D. Roth, Qingwen Cheng, Airi Harui, Saroj K. Basak, Kohnosuke Mitani, Teresa A. Low, Sylvia M. Kiertscher	2002	50
14	Microbial Lipopeptides Stimulate Dendritic Cell Maturation Via Toll-Like Receptor 2 The Journal of Immunology ·Cheryl J. Hertz, Sylvia M. Kiertscher, Paul J. Godowski, Deborah A. Bouis, Michael V. Norgard, Michael D. Roth, Robert L. Modlin	2001	297
15	Activation of Toll-Like Receptor 2 on Human Dendritic Cells Triggers Induction of IL-12, But Not IL-10 The Journal of Immunology ·Sybille Thoma-Uszynski, Sylvia M. Kiertscher, María Teresa Ochoa, Deborah A. Bouis, Michael V. Norgard, Kensuke Miyake, Paul J. Godowski, Michael D. Roth, Robert L. Modlin	2000	204
16	Airway Inflammation in Young Marijuana and Tobacco Smokers American Journal of Respiratory and Critical Care Medicine ·Michael D. Roth, Ashim Arora, Sanford H. Barsky, Eric C. Kleerup, Michael Simmons, Donald P. Tashkin	1998	168
17	Marijuana and Cocaine Impair Alveolar Macrophage Function and Cytokine Production American Journal of Respiratory and Critical Care Medicine ·Gayle Cocita Baldwin, Donald P. Tashkin, Dawn M. Buckley, ALICE N. PARK, Steven M. Dubinett, Michael D. Roth	1997	184
18	Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. The Journal of Experimental Medicine ·Michael D. Roth	1994	53
19	Inhibition of Natural Killer Cell Activity by Therapeutic Levels of Theophylline American Journal of Respiratory Cell and Molecular Biology ·Lawrence A. Coskey, John Bitting, Michael D. Roth	1993	13
20	Pulmonary Macrophages Suppress the Proliferation and Cytotoxicity of Tumor-infiltrating Lymphocytes American Journal of Respiratory Cell and Molecular Biology ·Stephen G. Swisher, Sylvia M. Kiertscher, Sidney H. Golub, E. Carmack Holmes, Michael D. Roth	1993	15

About Michael D. Roth

Michael D. Roth is a scholar working on Pathology and Forensic Medicine, Immunology, Pulmonary and Respiratory Medicine, Pharmacology and Virology, having authored 125 papers that have together received 6.9k indexed citations. Recurring topics across this work include Systemic Sclerosis and Related Diseases (42 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (39 papers), Immunotherapy and Immune Responses (22 papers), Inflammatory Myopathies and Dermatomyositis (21 papers), Cannabis and Cannabinoid Research (20 papers), Immune Cell Function and Interaction (20 papers), T-cell and B-cell Immunology (8 papers) and Immune Response and Inflammation (8 papers). The work is most often cited by research in Immunology (2.2k citations), Pathology and Forensic Medicine (1.8k citations), Pharmacology (1.5k citations), Biological Psychiatry (193 citations) and Pulmonary and Respiratory Medicine (2.1k citations). Michael D. Roth has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Donald P. Tashkin, Sylvia M. Kiertscher, Steven M. Dubinett, Gayle Cocita Baldwin, Jonathan Goldin, Philip J. Clements, Dinesh Khanna, Robert M. Elashoff, Daniel E. Furst and Theodore A. Sarafian. Their work appears in journals such as CHEST Journal, Annals of the Rheumatic Diseases, American Journal of Respiratory and Critical Care Medicine, Journal of Leukocyte Biology and Journal of Neuroimmune Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact